Carolina Liquid Chemistries Offers COVID-19 Rapid Screen Antibody Test
By HospiMedica International staff writers Posted on 02 Apr 2020 |
Image: COVID-19 Rapid Screen Antibody Test (Photo courtesy of Carolina Liquid Chemistries, Corp.)
Carolina Liquid Chemistries, Corp. (CLC; Greensboro, NC, USA) has begun offering its AllTest 2019-nCoV IgG/IgM Rapid Screen Antibody Test Cassette, a lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies to 2019-nCoV in human whole blood, serum or plasma specimen.
CLC is a manufacturer, repackager/relabeler, distributor, and technical service provider of chemistry systems and reagents for clinical and toxicology laboratories. The company offers chemistry analyzers that range in throughput from 300 to 6,400 tests per hour and markets a wide menu of general chemistry, special chemistry, and toxicology reagents.
CLC’s 2019-nCoV IgG/IgM Rapid Test Cassette can be performed using whole blood (from venipuncture or fingerstick), serum or EDTA plasma (K2, Heparin sodium, Citrate sodium and Potassium Oxalate). Internal procedural controls are included in the cassette and the test can be stored sealed at room temperature or refrigerated.
CLC has validated the test and tested its cross-reactivity for ani-influenza A virus and anti-influenza B virus, anti-RSV, anti-adenovirus, HBsAg, anti-Syphyllis, anit-H.Pylori, and anti-HIV and anti-HCV positive specimens. The results have shown no cross-reactivity. In comparison with commercially available PCR, CLC’s 2019-nCoV IgG/IgM Rapid Test Cassette’s performance results show that it has a high sensitivity and specificity.
“These are unprecedented times,” said Phillip Shugart, Chief Executive Officer of Carolina Liquid Chemistries. “The rapid screen is a fast and easy screen for antibodies that compliments other tests and symptoms to give a fuller picture.”
Related Links:
Carolina Liquid Chemistries, Corp.
CLC is a manufacturer, repackager/relabeler, distributor, and technical service provider of chemistry systems and reagents for clinical and toxicology laboratories. The company offers chemistry analyzers that range in throughput from 300 to 6,400 tests per hour and markets a wide menu of general chemistry, special chemistry, and toxicology reagents.
CLC’s 2019-nCoV IgG/IgM Rapid Test Cassette can be performed using whole blood (from venipuncture or fingerstick), serum or EDTA plasma (K2, Heparin sodium, Citrate sodium and Potassium Oxalate). Internal procedural controls are included in the cassette and the test can be stored sealed at room temperature or refrigerated.
CLC has validated the test and tested its cross-reactivity for ani-influenza A virus and anti-influenza B virus, anti-RSV, anti-adenovirus, HBsAg, anti-Syphyllis, anit-H.Pylori, and anti-HIV and anti-HCV positive specimens. The results have shown no cross-reactivity. In comparison with commercially available PCR, CLC’s 2019-nCoV IgG/IgM Rapid Test Cassette’s performance results show that it has a high sensitivity and specificity.
“These are unprecedented times,” said Phillip Shugart, Chief Executive Officer of Carolina Liquid Chemistries. “The rapid screen is a fast and easy screen for antibodies that compliments other tests and symptoms to give a fuller picture.”
Related Links:
Carolina Liquid Chemistries, Corp.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans